First Patient Receives World-First Brain Cancer Treatment

In exciting news, the first patient in our joint clinical trial with QIMR Berghofer Medical Research Institute into a new treatment for brain cancer, has received the first dose of the world-first treatment. Sarah, who is from NSW, travelled to Brisbane last week to receive the first part of the combination immunotherapy in Phase I of the clinical trial.

Sarah was diagnosed with glioblastoma multiforme (GBM) in 2022. GBM is a particularly fast growing and aggressive form of brain cancer which, currently, is almost always fatal. Sarah underwent emergency surgery to remove the tumour following the shock diagnosis. Initially, the surgery was deemed successful but the tumour came back (recurrence) which is a common outcome for patients diagnosed with GBM.

The world-first treatment combines two different cancer treatments which involves receiving a number of infusions over a set period of time. Sarah will receive continue to receive infusions over the coming months in line with the protocol developed by the research team under the supervision of her oncologist and other treating doctors.

It is hoped that this treatment will provide Sarah with a longer and better quality of life, and ultimately lead to a cure for brain cancer. We will follow Sarah's journey and keep you posted!